Intensity Therapeutics closed at $3.10 on Nov 5, down 11.43%, within 0.0% of its 52-week closing low. Volume of 50.2K shares was 2.71× its 20-day average (well above normal).
Split-adjusted performance: -18.4% over one month, -39.3% over six months, -76.8% over one year.
Short interest was 87.8K shares at the Oct 15 settlement, up 129.4% from the prior report (2.9% of float, 3.0 days to cover).
No reported quarters with price history yet.
Percentile among 139 companies (100 = best)
Industry medians: 6-month return −24.8%, revenue growth +8.5%, net margin −226.4%, P/E 21.0×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| INTSIntensity Therapeutics | $3.10 | −11.43% | −39.3% | — | — | — | $10.1M | |
| PASGPassage Bio | $3.46 | −1.42% | −15.2% | — | — | — | $11.1M | Compare |
| SCLXScilex Holding | $1.70 | −7.10% | −78.9% | −22.8% | −1501.3% | — | $12.0M | Compare |
| TCRXTScan Therapeutics | $0.1818 | −13.43% | −85.0% | −65.8% | −2888.6% | — | $12.3M | Compare |
| INABIN8bio | $0.8300 | −10.82% | −48.1% | — | — | — | $8.2M | Compare |
| BCDABioCardia | $0.8900 | −2.53% | −18.3% | — | — | — | $13.5M | Compare |
| DYAIDyadic International | $0.3401 | −7.25% | −54.3% | −0.6% | −221.0% | — | $13.6M | Compare |
| ATYRaTyr Pharma | $6.03 | −2.43% | −83.6% | — | — | — | $15.1M | Compare |
| ABOSAcumen Pharmaceuticals | $0.2138 | −1.16% | −91.3% | — | — | — | $15.5M | Compare |
No recent articles focused on Intensity Therapeutics.
Intensity Therapeutics Inc is a late-stage clinical biotechnology company passionately committed to applying scientific leadership in the field of localized cancer reduction to anti-cancer immune activation. Its new approach involves the direct injection into tumors of a product created from DfuseRxSM discovery platform. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its product candidate, INT230-6 comprised of three components: cisplatin, a anti-cancer cytotoxic agent, vinblastine sulfate, also a anti-cancer cytotoxic agent, and an amphiphilic molecule which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
